# US 2023/0067770 A1 · Anti-cd137 constructs, multispecific antibody and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0067770 A1
- Document ID: US20230067770A1
- Status: Published application
- Kind: A1
- Application number: 17/822,737
- Filed: 2022-08-26
- Published: 2023-03-02
- Earliest claimed: 2020-02-28
- Assignees: Shanghai Henlius Biotech, Inc.
- Applicants: Shanghai Henlius Biotech, Inc.
- Inventors: Jie XUE; Wei-Dong JIANG; Wenfeng XU; Weijun FENG
- Web page: https://patentgrep.com/patent/US20230067770A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides anti-CD137 constructs that bind to CD137, including multispecific anti-CD137 antibodies with binding specificity for CD137 and one or more additional antigen, and methods of using the same. In certain embodiments, the one or more additional antigen comprises epidermal growth factor receptor (EGFR).

## Claims

### Claim 1

A multispecific antibody that binds to CD137 and EGFR, comprising a first antibody moiety that binds to CD137 and a second antibody moiety that binds to EGFR;
wherein the first antibody moiety comprises a heavy chain variable region (VH) comprising HC-CDR1, HC-CDR2 and HC-CDR3 domains and a light chain variable region (VL) comprising LC-CDR1, LC-CDR2 and LC-CDR3 domains that are selected from the group consisting of:
a) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 3, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 4, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 6;
b) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 11, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 13, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 14, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 15, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16;
c) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 21, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 22, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 23, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 24, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 25, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 26;
d) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 31, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 32, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 33, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 34, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 35, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 36;
e) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 41, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 42, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 44, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 45, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 46;
f) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 53, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 54, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 55, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56;
g) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 61, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 63, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 64, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 65, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 66;
h) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 71, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 72, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 73, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 74, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 75, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 76;
i) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 81, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 82, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 83, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 84, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 85, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 86;
i) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 91, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 93, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 94, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 95, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 96;
k) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 101, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 102, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 103, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 104, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 105, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 106;
l) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 111, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 112, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 113, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 114, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 115, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 116;
m) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 121, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 122, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 123, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 124, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 125, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 126;
n) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 131, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 132, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 133, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 134, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 135, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 136;
o) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 261, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 262, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 263, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 264, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 265, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 266; and
p) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 271, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 272, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 273, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 274, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 275, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 276.

### Claim at position 2

2-17. (canceled)

### Claim 18 (depends on 1)

The multispecific antibody of claim 1, wherein the first antibody moiety comprises a heavy chain variable region (VH) that comprises HC-CDR1, HC-CDR2, and HC-CDR3 domains; and a light chain variable region (VL) that comprises LC-CDR1, LC-CDR2, and LC-CDR3 domains, wherein the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 121, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 122, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 123, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 124, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 125, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 126.

### Claim at position 4

19-20. (canceled)

### Claim 21 (depends on 1)

The multispecific antibody of claim 1, wherein the first antibody moiety comprises a heavy chain variable region (VH) that comprises HC-CDR1, HC-CDR2, and HC-CDR3 domains; and a light chain variable region (VL) that comprises LC-CDR1, LC-CDR2, and LC-CDR3 domains, wherein the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 261, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 262, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 263, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 264, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 265, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 266.

### Claim at position 6

22-23. (canceled)

### Claim 24 (depends on 1)

The multispecific antibody of claim 1, wherein the first antibody moiety comprises:
(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 7; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 8;
(b) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 17; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 18;
(c) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 27; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 28;
(d) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 37; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 38;
(e) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 47; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 48;
(f) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 57; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 58;
(g) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 67; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 68;
(h) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 77; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 78;
(i) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 87; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 88;
(j) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 97; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 98;
(k) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 107; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 108;
(l) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 117; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 118;
(m) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 127; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 128;
(n) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 137; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 138;
(o) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 267; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 268; or
(p) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 277; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 278.

### Claim at position 8

25-26. (canceled)

### Claim 27 (depends on 1)

The multispecific antibody of claim 1, wherein the first antibody moiety comprises an antibody or antigen-binding fragment thereof selected from the group consisting of a full-length antibody, a multispecific antibody (e.g., a bispecific antibody), a single-chain Fv (scFv), a Fab fragment, a Fab′ fragment, a F(ab′)2, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a VHH, a Fv-Fc fusion, a scFv-Fc fusion, a scFv-Fv fusion, a diabody, a tribody, and a tetrabody.

### Claim at position 10

28-29. (canceled)

### Claim 30 (depends on 1)

The multispecific antibody of any one of claim 1, wherein the first antibody moiety is a CD137 agonist antibody.

### Claim at position 12

31-46. (canceled)

### Claim 47 (depends on 1)

The multispecific antibody of claim 1, wherein the second antibody moiety comprises an Fc region selected from the group consisting of Fc regions from IgG1, IgG2, IgG3, IgG4, and any combinations and hybrids thereof.

### Claim at position 14

48-49. (canceled)

### Claim 50 (depends on 47)

The multispecific antibody of claim 47, wherein the Fc region comprises an IgG1 Fc region.

### Claim 51 (depends on 50)

The multispecific antibody of claim 50, wherein the IgG1 Fc region comprises a L234A mutation and a L235A mutation.

### Claim 52 (depends on 47)

The multispecific antibody of claim 47, wherein the Fc region comprises an IgG4 Fc region.

### Claim 53 (depends on 52)

The multispecific antibody of claim 52, wherein the IgG4 Fc region comprises a F234A mutation and a L235A mutation.

### Claim 54 (depends on 52)

The multispecific antibody of claim 52, wherein the IgG4 Fc region comprises a S228P mutation.

### Claim at position 20

55-56. (canceled)

### Claim 57 (depends on 1)

The multispecific antibody of claim 1, wherein the second antibody moiety comprises a full length antibody that binds to EGFR and comprises a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2), wherein:
a) the VH-2 comprises an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 190, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 191, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 192; and the VL-2 comprises an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 193, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 194, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 195;
b) the VH-2 comprises an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 198, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 199, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 200; and the VL-2 comprises an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 201, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 202, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 203;
c) the VH-2 comprises an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 206, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 207, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 208; and the VL-2 comprises an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 209, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 210, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 211;
d) the VH-2 comprises an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 214, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 215, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 216; and the VL-2 comprises an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 217, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 218, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 219; or
e) the VH-2 comprises an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 222, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 223, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 224; and the VL-2 comprises an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 225, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 226, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 227.

### Claim at position 22

58-59. (canceled)

### Claim 60 (depends on 1)

The multispecific antibody of claim 1, wherein the VH-2 comprises an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 206, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 207, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 208; and the VL-2 comprises an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 209, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 210, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 211.

### Claim at position 24

61-63. (canceled)

### Claim 64 (depends on 1)

The multispecific antibody of claim 1, wherein
a) the VH-2 comprises the amino acid sequence of SEQ ID NO: 196; and the VL-2 comprises the amino acid sequence of SEQ ID NO: 197;
b) the VH-2 comprises the amino acid sequence of SEQ ID NO: 204; and the VL-2 comprises the amino acid sequence of SEQ ID NO: 205;
c) the VH-2 comprises the amino acid sequence of SEQ ID NO: 212; and the VL-2 comprises the amino acid sequence of SEQ ID NO: 213;
d) the VH-2 comprises the amino acid sequence of SEQ ID NO: 220; and the VL-2 comprises the amino acid sequence of SEQ ID NO: 221; or
e) the VH-2 comprises the amino acid sequence of SEQ ID NO: 228; and the VL-2 comprises the amino acid sequence of SEQ ID NO: 229.

### Claim 65 (depends on 64)

The multispecific antibody of claim 64, comprising:
a) the first antibody moiety comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 121, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 122, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 123, and the VL comprises an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 124, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 125, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 126; and
b) the second antibody moiety comprises a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2), wherein the VH-2 comprises a second HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 206, a second HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 207, and a second HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 208; and the VL-2 comprises a second LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 209, a second LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 210, and a second LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 211.

### Claim 66 (depends on 1)

The multispecific antibody of claim 1, comprising:
a) the first antibody moiety comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 261, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 262, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 263, and the VL comprises an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 264, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 265, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 266; and
b) the second antibody moiety comprises a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2), wherein the VH-2 comprises a second HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 206, a second HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 207, and a second HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 208; and the VL-2 comprises a second LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 209, a second LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 210, and a second LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 211.

### Claim 67

(canceled)

### Claim 68 (depends on 1)

The multispecific antibody of claim 1, comprising i) a heavy chain of an anti-EGFR full length antibody fused to an anti-CD137 single chain Fv fragment which comprises an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 183, 185, 188, 189, 230, 231, 259, 260, 281 or 282; and ii) a light chain of an anti-EGFR full length antibody comprising an amino acid sequence having at least about 90% sequence identity to an amino acid sequence of SEQ ID NO: 184, 186 or 187.

### Claim 69 (depends on 68)

The multispecific antibody of claim 68, comprising i) a heavy chain of the anti-EGFR full length antibody fused to an anti-CD137 single chain Fv fragment which comprises an amino acid sequence of any one of SEQ ID NOs: 183, 185, 188, 189, 230, 231, 259, 260, 281 or 282; and ii) a light chain of an anti-EGFR full length antibody comprising an amino acid sequence of SEQ ID NO: 184, 186 or 187.

### Claim at position 31

70-83. (canceled)

### Claim 84 (depends on 1)

An immunoconjugate comprising the multispecific antibody of claim 1, linked to a therapeutic agent or a label.

### Claim 85

(canceled)

### Claim 86 (depends on 1)

A pharmaceutical composition comprising the multispecific antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim 87 (depends on 1)

An isolated nucleic acid encoding the multispecific antibody of claim 1.

### Claim 88 (depends on 87)

A vector comprising the isolated nucleic acid of claim 87.

### Claim 89 (depends on 87)

An isolated host cell comprising the isolated nucleic acid of claim 87.

### Claim 90 (depends on 89)

A method of producing a multispecific antibody, comprising:
a) culturing the isolated host cell of claim 89 under conditions effective to express the multispecific antibody; and
b) obtaining the expressed multispecific antibody from the host cell.

### Claim 91 (depends on 86)

A method of treating or preventing a disease in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 86.

### Claim at position 40

92-101. (canceled)

### Claim 102 (depends on 1)

A kit comprising the multispecific antibody of claim 1.

### Claim 103

(canceled)
